In:
International Journal of Cancer, Wiley, Vol. 136, No. 4 ( 2015-02-15), p. 936-944
Abstract:
What's new? Cetuximab, an anti‐EGFR monoclonal antibody (mAb), is used in combination with chemotherapy for several types of cancer. While many studies evaluating the toxicity of mAbs have focused on fatal adverse events, less severe toxic effects can still have a major impact on patient health. In this meta‐analysis, the authors found that there is a slight but significant increase in the risk of severe hematologic toxicity associated with cetuximab treatment. Rigorous hematological monitoring of a patient's peripheral hemogram is therefore warranted when cetuximab is part of a treatment regimen.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink